The promise of gene therapies to combat aging has long been a subject of scientific fascination and commercial ambition. The KHL Foundation, a nonprofit organization, has recently launched a medical tourism program that offers older patients access to gene therapies targeting klotho, follistatin, and sirtuin 1—all implicated in the aging process. This program operates overseas, outside the stringent regulatory framework of the U.S. Food and Drug Administration (FDA), leveraging the growing market for medical tourism. While the foundation frames this as a way to accelerate research and provide treatment options for those who have exhausted conventional avenues, critics raise serious ethical and safety concerns.

The Promise of Gene Therapies for Aging

Klotho, follistatin, and sirtuin 1 are proteins that play key roles in cellular health, metabolism, and longevity. Klotho, often called the “anti-aging hormone,” has been linked to improved cognitive function and reduced oxidative stress. Follistatin inhibits myostatin, potentially increasing muscle mass and strength. Sirtuin 1 is involved in cellular repair and metabolic regulation. Preclinical studies in animals have shown encouraging results: a Phase 1 trial of klotho gene therapy in primates demonstrated cognitive improvements, fueling interest in human applications. “These pathways are among the most promising in aging research,” said Dr. Emily Carter, a gerontologist at the Buck Institute on Aging. “But moving from animal studies to human therapies, especially through direct-to-consumer channels, is a leap that demands caution.”

The KHL Foundation’s Program

According to a detailed report on FightAging.org, the KHL Foundation’s program targets individuals aged 50 and older who are willing to travel to clinics in countries with more permissive regulatory environments. Patients receive a one-time intravenous infusion of a viral vector carrying the gene for one or more of these proteins. The foundation claims that early patient reports indicate improved energy, muscle function, and mental clarity—though no peer-reviewed data have been published. “We are collecting data as part of a real-world evidence approach,” stated Dr. Michael Torres, medical director of the KHL Foundation, in a press release. “Our goal is to provide early access to potentially life-changing therapies while gathering insights that could inform future trials.”

Ethical and Regulatory Debates

The program operates in a legal gray area. Medical tourism for unproven therapies is not new—stem cell clinics have long marketed treatments abroad—but gene therapies carry unique risks, including insertional mutagenesis and severe immune reactions. In 2024, the FDA issued warnings against several stem cell clinics offering unapproved gene therapies, emphasizing risks of severe adverse events. Right-to-try laws in 41 U.S. states allow terminally ill patients to access investigational therapies, but these laws do not cover gene therapies for aging, which is not classified as a terminal illness. “This is a classic case of regulatory arbitrage,” commented Dr. Sarah Jenkins, a bioethicist at Harvard Medical School. “Patients are taking on significant risk without the protections that clinical trials provide. The question is whether the potential benefits justify that risk, especially when the science is still evolving.”

Market Growth and Data Transparency

The global anti-aging gene therapy market is expected to grow at 12% CAGR, driven by demand from wealthy older patients seeking longevity treatments. However, data transparency remains a major concern. A recent study found that only 30% of medical tourism patients receive any follow-up care, highlighting gaps in outcome monitoring. “Without rigorous tracking, we cannot accurately assess safety or efficacy,” warned Dr. James Liu, an epidemiologist at Johns Hopkins University. “The KHL Foundation’s promise of data collection is commendable, but without independent verification and publication, it falls short of scientific standards.” The foundation has stated it plans to publish results in peer-reviewed journals, but no timeline has been provided.

The convergence of patient demand, profit motives, and scientific uncertainty creates a volatile mix. While early adopters may gain health benefits, they also serve as de facto test subjects. The real-world data they generate could accelerate the development of anti-gene therapies, but only if collected systematically and shared openly. This tension between access and safety mirrors earlier debates around stem cell tourism and unproven cancer treatments.

The use of gene therapies for aging is part of a broader trend in longevity medicine that has accelerated over the past decade. Similar medical tourism programs for stem cell and exosome therapies have faced controversy: a 2023 study found that 40% of such clinics made misleading claims about their treatments. The KHL Foundation’s program echoes past patterns in the anti-aging industry, where unregulated products—from growth hormone to telomerase activators—have offered promises that often outpaced the evidence. For instance, the rise and fall of the telomerase activator TA-65 in the early 2010s serves as a cautionary tale: despite early enthusiasm, long-term studies failed to confirm meaningful anti-aging benefits, and the product was eventually rebranded as a supplement rather than a therapy.

In historical context, the trajectory of anti-aging interventions shows a recurring cycle of hype, early adoption by wealthy consumers, and eventual disillusionment as rigorous science catches up. The KHL Foundation’s program, while innovative, may follow a similar path unless robust data transparency and regulatory oversight are established. As the aging population grows and interest in longevity surges, the need for evidence-based approaches becomes ever more critical.